BOSTON, Mass. (
) -- A calendar of important, potentially stock-moving biotech events for February:
: Surfaxin regulatory update conference call.
: 36-month results from phase III study of Iluvien in diabetic macular edema.
( AEN) investor/analyst day.
BIO CEO & Investor Conference, New York City.
Expiration of Sanofi-Aventis' $69-a-share tender offer for
: Presentation of updated cabozantinib (XL184) data in prostate cancer at ASCO GU symposium
: FDA approval decision date for Uplyso in Gaucher's disease.
Other potential February events
: FDA decision on lifting clinical hold on hepatitis C drugs IDX184 and IDX320.
( AMLN), Alkermes,
: Start of a Bydureon Qt study.
Source: Company reports, BioMedTracker.com
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.